These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30851897)

  • 1. Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma.
    Xu Y; Wang H; Zeng Y; Tian Y; Shen Z; Xie Z; Chen F; Sun L; Shu R; Li PP; Chen C; Yu J; Wang K; Luo H
    Surg Oncol; 2019 Mar; 28():180-189. PubMed ID: 30851897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
    Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
    Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.
    Chen W; Chen L; Cai Z; Liang D; Zhao B; Zeng Y; Liu X; Liu J
    Tumour Biol; 2016 Jul; 37(7):9343-55. PubMed ID: 26779633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
    Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression.
    Duan M; Wang ZC; Wang XY; Shi JY; Yang LX; Ding ZB; Gao Q; Zhou J; Fan J
    Ann Surg Oncol; 2015 Sep; 22(9):3121-9. PubMed ID: 25465376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
    Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
    Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic function and prognostic significance of Abelson interactor 1 in hepatocellular carcinoma.
    Wang JL; Yan TT; Long C; Cai WW
    Int J Oncol; 2017 May; 50(5):1889-1898. PubMed ID: 28339046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma.
    Zhou ZJ; Dai Z; Zhou SL; Fu XT; Zhao YM; Shi YH; Zhou J; Fan J
    Int J Cancer; 2013 Mar; 132(5):1080-9. PubMed ID: 22821376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.
    Jin Y; Li Q; Qiu J; Zhao X; Zheng C; Lv S; Bai Y; Shan Y; Ye LC
    Tumour Biol; 2016 Oct; 37(10):14193-14203. PubMed ID: 27553024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.
    Zheng H; Jiang WH; Tian T; Tan HS; Chen Y; Qiao GL; Han J; Huang SY; Yang Y; Li S; Wang ZG; Gao R; Ren H; Xing H; Ni JS; Wang LH; Ma LJ; Zhou WP
    Oncotarget; 2017 Mar; 8(12):18872-18884. PubMed ID: 28122351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
    Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
    Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
    Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
    Ying D; Ruan Y; Zhou X
    Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma.
    Tao QF; Yuan SX; Yang F; Yang S; Yang Y; Yuan JH; Wang ZG; Xu QG; Lin KY; Cai J; Yu J; Huang WL; Teng XL; Zhou CC; Wang F; Sun SH; Zhou WP
    Mol Cancer; 2015 Sep; 14():170. PubMed ID: 26376879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
    Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
    Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
    Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
    Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma.
    Zhang L; Jia G; Shi B; Ge G; Duan H; Yang Y
    Cell Physiol Biochem; 2016; 40(3-4):757-769. PubMed ID: 27915333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.